Share This Article:

Will High Dose Rate Interstitial Brachytherapy Be a Surrogate to Surgery in Early Mobile Squamous Cell Carcinoma of Tongue—An Indian Experience

Abstract Full-Text HTML Download Download as PDF (Size:2618KB) PP. 143-155
DOI: 10.4236/ijmpcero.2014.33020    2,218 Downloads   2,737 Views  

ABSTRACT

The study was intended to highlight functional outcome and survival advantage when High Dose Rate (HDR) interstitial implant was used for anterior 2/3rd tongue, either as a primary or as boost depending upon stage of disease. Materials and Methods: Fifty-one patients with squamous cell carcinoma of anterior 2/3rd tongue received interstitial brachytherapy either as primary or as boost with Iridium 192 remote after loading high dose rate (Microselectron or Gamma MediX) machines from November 2008 to September 2013. Age group ranged from 32 to 73 years, mean 52.1. Of these 51, 37 were males and 14 were females. 8 patients belonged to Stage I, 18 from Stage II and 28 patients were Stage III. Stage I patients received primary brachytherapy alone of dose 38.50 Gy to 40 Gy and fraction dose ranged from 250 cGy to 350 cGy. Stage II and Stage III patients received external beam radiation of dose 44 Gy/200cGy per fraction for 22 fractions followed by spinal cord sparing for 6 Gy/200cGy per fraction for 3 fractions. Brachytherapy boost of dose 21 Gy was delivered after external beam radiation. Stage III patients received concurrent chemotherapy with Injection Cisplatin along with external beam radiotherapy 44 Gy/200cGy per fraction for 22 fractions followed by spinal cord sparing for 6 Gy/200cGy per fraction for 3 fractions. Brachytherapy boost of dose 21 Gy was delivered after external beam radiation. 55% of patients were habituated to tobacco and alcohol in one form or the other or both. Surprisingly 45% of patients were nonsmokers and non-alcoholic. Results: Follow-up period ranged from eight months to sixty months. 42 patients had complete response. 9 patients had residual disease. 2 patients died due to non-cancerous cause though they had excellent local control, one with pulmonary tuberculosis and the other with massive Myocardial Infarction. 2 patients died due to disease progression.

Overall complete response rate was 82.35%. Those patients who had good coverage index and conformal index had good response compared to those patients with lesser these values. Conclusion: It is surprising to observe from the study that oral cavity cancers are not uncommon in non-smokers and non-alcoholics. Overall complete response of 82% is comparable to any other study quoted in literature. Surgery offers same cure rate but at the rate of organ loss and functional impairment. Organ preservation with good functional outcome is possible in radiotherapy unlike surgery. This study proves brachytherapy can be considered as a surrogate to surgery in early stage tongue cancers with good functional outcome and with lesser morbidity.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Vedasoundaram, P. , Reddy, K. , Selvarajan, G. , Kandasamy, S. , Sinnathambi, M. , Asif, M. and Singhavajhala, V. (2014) Will High Dose Rate Interstitial Brachytherapy Be a Surrogate to Surgery in Early Mobile Squamous Cell Carcinoma of Tongue—An Indian Experience. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 3, 143-155. doi: 10.4236/ijmpcero.2014.33020.

References

[1] Ballonoff, A. and Chen, C. (2006) Current Radiation Therapy Management Issues in Oral Cavity Cancer. Otolaryngologic Clinics of North America, 39, 365-380.
[2] Taktak, A.F.G. and Fisher, A.C. (2007) Outcome Predictions in Cancer. Elsevier, Amsterdam, 1-14.
[3] Coelho, K.R. (2012) Challenges of the Oral Cancer Burden in India. Journal of Cancer Epidemiology, 2012, Article ID: 701932.
[4] Khan, Z.U. (2012) An Overview of Oral Cancer in Indian Sub-Continent and Recommendation to Decrease Its Incidence. Webmed Central Cancer, 3, Article ID: WMC003626.
[5] Jemal, A., Bray, F., Center, M.M., Ferlay, J. and Ward, E. (2011) Global Cancer Statistics. A Cancer Journal for Clinicians, 61, 69-90.
[6] Hiratsuka, H., Miyakawa, A., Nakamori, K., et al. (1997) Multivariate Analysis of Occult Lymph Node as a Prognostic Indicator for Patients with Squamous Cell Carcinoma for the Oral Cavity. Cancer, 80, 351-356.
[7] Shear, M. and Hawkins, D.M. (1976) The Prediction of Lymph Node Metastases from Oral Squamous Cell Carcinoma. Cancer, 37, 1901-1907.
http://dx.doi.org/10.1002/1097-0142(197604)37:4<1901::AID-CNCR2820370440>3.0.CO;2-U
[8] Halperin, E.C., Brady, L.W., Perez, C.A. and Wazer, D.E. (2008) Perez and Brady’s Principles and Practice of Radiation Oncology. 5th Edition, Lippincott Williams & Wilkins (LWW), Philadelphia, 891-912.
[9] Globocan (2012) Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer, Lyon.
http://globocan.iarc.fr
[10] Llewellyn, C.D., Johnson, N.W. and Warnakulasuriya, K.A.A.S. (2001) Risk Factors for Squamous Cell Carcinoma of Oral Cavity in Foms People; a Comprehensive Literature Review. Oral Oncology, 37, 401-418.
http://dx.doi.org/10.1016/S1368-8375(00)00135-4
[11] Miller, C.S. and Johnstone, B.M. (2001) Human Papillomavirus as a Risk Factor for Oral Squamous Cell Carcinoma, a Meta-Analysis 1982-1997. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 91, 622-635.
http://dx.doi.org/10.1067/moe.2001.115392
[12] Myers, E. (2003) Cancer of the Head and Neck. Saunders, Philadelphia.
[13] Maden, C., Beckmann, A.M., et al. (1992) Human Papillomavirus, Herpes Simplex Virus and the Risk of Oral Cancer in Men. American Journal of Epidemiology, 135, 1093-1102.
[14] O’ Brien, C.J., Lahr, C.J., Soong, S.J., Gandour, M.J., et al. (1986) Surgical Treatment of Early Stage Carcinoma of the Oral Tongue—Would Adjuvant Treatment Be Beneficial. Head and Neck Surgery, 8, 401-408.
http://dx.doi.org/10.1002/hed.2890080603
[15] Kolokythas, A. (2010) Long Term Surgical Complications in the Oral Cancer Patient: A Comprehensive Review—Part I. J Oral Maxillofac Res., 1, e1.
http://dx.doi.org/10.5037/jomr.2010.1301
[16] Kolokythas, A. (2010) Long Term Surgical Complications in the Oral Cancer Patient: A Comprehensive Review—Part II. J Oral Maxillofac Res., 1, e2.
http://dx.doi.org/10.5037/jomr.2010.1301
[17] Studer, G., Zwahlen, R.A., et al. (2007) IMRT in Oral Cavity Cancer. Radiation Oncology, 2, 16.
http://dx.doi.org/10.1186/1748-717X-2-16
[18] Matsui, Y. and Ohno, K. (2007) Factors Influencing Post-Operative Speech Function of Tongue Cancer Patients Following Reconstruction with Fasciocutaneous/Myocutaneous Flaps—A Multi Centre Study. International Journal of Oral and Maxillofacial Surgery, 36, 601-609.
http://dx.doi.org/10.1016/j.ijom.2007.01.014
[19] Kellas-Sleczka, S., et al. (2010) Interstitial HDR Brachytherapy in Early Stage Mobile Tongue Caners in Young Patient—Gliwice Experience. Journal of Contemporary Brachytherapy, 2, 61-63.
[20] Sresty, N.V. and Ramanjappa, T. (2010) Acquisition of Equal or Better Planning Results with Interstitial Brachytherapy When Compared with Intensity Modulated Radiotherapy in Tongue Cancers. Brachytherapy, 9, 235-238.
http://dx.doi.org/10.1016/j.brachy.2009.05.006
[21] Niladri, B. and Patra, J.G., et al. (2009) Outcome of High Dose Rate Interstitial Boost Brachytherapy Afterexternal Beam Radiation Therapy in Head and Neck Cancer. An Indian (Single Institutional) Learning Experience. Brachytherapy, 8, 248-254.
http://dx.doi.org/10.1016/j.brachy.2008.12.006
[22] Emami, B. and Lyman, J. (1991) Tolerance of Normal Tissue to Therapeutic Irradiation. International Journal of Radiation Oncology*Biology*Physics, 21, 109-122.
[23] Devlin, P.M. (2007) Brachytherapy Applications and Techniques. Lippincott Williams & Wilkins, Philladelphia, 63.
[24] Oota, S. and Shibuya, H. (2006) Brachytherapy of Stage II Mobile Tongue Carcinoma. Prediction of Local Control and QOL. Radiation Oncology, 1, 21.
http://dx.doi.org/10.1186/1748-717X-1-21
[25] Fujita, M. and Hirokawa, Y. (1996) An Analysis of Mandibular Bone Complications in Radiotherapy for T1 and T2 Carcinoma of the oral Tongue. International Journal of Radiation Oncology*Biology*Physics, 34, 333-339.
[26] Mazeron, J.-J., Ardiet, J.-M., et al. (2009) GEC-ESTRO Recommendations for Brachytherapy for Head and Neck Squamous Cell Carcinomas. Radiotherapy and Oncology, 91, 150-156.
http://dx.doi.org/10.1016/j.radonc.2009.01.005
[27] Feuvret, L. and Noel, G. (2006) Conformity Index; a Review. International Journal of Radiation Oncology*Biology*Physics, 64, 333-342.
http://dx.doi.org/10.1016/j.ijrobp.2005.09.028
[28] Kehwar, T.S. and Akber, S.F. (2008) Qualitative Dosimetric and Radiobiological Evaluation of High Dose Rate Interstitial Brachytherapy Implants. International Journal of Medical Sciences, 5, 41-49.
http://dx.doi.org/10.7150/ijms.5.41

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.